The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease
Na Li, Liyuan Hao, Shenghao Li, Jiali Deng, Fei Yu, Junli Zhang, Aiyu Nie, Xiaoyu Hu · 2024
Read The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease by Na Li, Liyuan Hao, Shenghao Li, Jiali Deng, Fei Yu, Junli Zhang, Aiyu Nie, Xiaoyu Hu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11542495.txt.
Description
Na Li and her seven co-authors review, in a 2024 paper, a cell defense pathway that might become a drug target for a common liver disease. The disease starts with fat building up in liver cells. It can worsen step by step into inflammation, scarring, and even liver cancer. Damage from unstable oxygen molecules, called oxidative stress, drives much of that decline.
The pathway under review switches on the cell's own protective genes. It fights the oxygen damage, calms inflammation, and helps cells avoid self-destruction. Many studies show that turning it up slows the liver disease in models. The review also lists natural compounds that protect the liver by activating this switch. The authors conclude the pathway is a strong candidate for future treatments, though the evidence so far is mostly preclinical.
Catalog record
| CREATOR | Na Li, Liyuan Hao, Shenghao Li, Jiali Deng, Fei Yu, Junli Zhang, Aiyu Nie, Xiaoyu Hu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |